Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Herein, we present the long-term follow-up of the randomized E1912 trial comparing the long-term efficacy of ibrutinib–rituximab (IR) therapy to fludarabine, cyclophosphamide, and rituximab (FCR) and describe the tolerability of continuous ibrutinib. The E1912 trial enrolled 529 treatment-naïve pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Shanafelt, Tait D., Wang, Xin Victoria, Hanson, Curtis A., Paietta, Elisabeth M., O’Brien, Susan, Barrientos, Jacqueline, Jelinek, Diane F., Braggio, Esteban, Leis, Jose F., Zhang, Cong Christine, Coutre, Steven E., Barr, Paul M., Cashen, Amanda F., Mato, Anthony R., Singh, Avina K., Mullane, Michael P., Little, Richard F., Erba, Harry, Stone, Richard M., Litzow, Mark, Tallman, Martin, Kay, Neil E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283968/
https://www.ncbi.nlm.nih.gov/pubmed/35427411
http://dx.doi.org/10.1182/blood.2021014960

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283968/
https://www.ncbi.nlm.nih.gov/pubmed/35427411
http://dx.doi.org/10.1182/blood.2021014960

Ejemplares similares